BidaskClub cut shares of BioScrip (NASDAQ:BIOS) from a buy rating to a hold rating in a report released on Friday.
Several other equities research analysts have also weighed in on BIOS. SunTrust Banks reiterated a buy rating and set a $3.00 price objective on shares of BioScrip in a research note on Friday, November 3rd. Zacks Investment Research lowered shares of BioScrip from a hold rating to a sell rating in a research note on Tuesday, November 7th. Finally, ValuEngine upgraded shares of BioScrip from a strong sell rating to a sell rating in a research note on Thursday, November 9th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $3.63.
Shares of BioScrip (BIOS) opened at $2.93 on Friday. BioScrip has a 12 month low of $1.35 and a 12 month high of $3.39. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/19/bioscrip-bios-lowered-to-hold-at-bidaskclub.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.